PTGX
$98.87-2.81 (-2.76%)
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in p...
Recent News
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.
A Look At Protagonist Therapeutics (PTGX) Valuation After FDA Approval Of ICOTYDE
FDA approval sets new context for Protagonist Therapeutics The recent U.S. FDA approval of ICOTYDE for moderate to severe plaque psoriasis puts Protagonist Therapeutics (PTGX) in a new phase. Attention is now shifting toward how this therapy might influence revenue, costs, and future development priorities. See our latest analysis for Protagonist Therapeutics. The FDA approval has arrived after a strong run in the shares, with a 23.31% 1 month share price return and a 91.67% 1 year total...
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval And What's Next
Protagonist Therapeutics recently received U.S. FDA approval for ICOTYDE (icotrokinra) to treat adults with moderate to severe plaque psoriasis, and held a special call on March 18, 2026 to discuss the decision. This first approval for ICOTYDE marks a key transition for Protagonist Therapeutics from a primarily development-stage biotech toward commercializing its own psoriasis therapy. We’ll now examine how ICOTYDE’s FDA approval for moderate to severe plaque psoriasis could reshape...